A phase IIb, Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group, Dose-Ranging Study of M610101 in Patients with Nonsegmental Vitiligo

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031260035

Enrollment

120

Registered

2026-04-10

Start date

2026-05-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-segmental vitiligo

Interventions

Apply 2 times a day.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Participants aged 12 years and older with a clinical diagnosis of non-segmental vitiligo (2) >=0.5 facial-VASI(F-VASI) score (3) >=3 total body-VASI(F-VASI) score

Exclusion criteria

Exclusion criteria: (1) Patients complicated with diseases considered inappropriate for participation in clinical trials such as serious cardiac / hepatic / renal / pulmonary / hematologic disease (2) Patients with non-segmental vitiligo or skin pigmentation disorders that may affect the evaluation or safety of the subject

Design outcomes

Primary

Measure	Time frame
Proportion of participants achieving F-VASI75 at Week 24.	—

Contacts

Public ContactClinical Trials Information -

Maruho Co.,Ltd. Kyoto R&D Center

ctinfo@mii.maruho.co.jp+81-75-325-3279

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026